Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Haloperidol

FDA-approved product (tablet, oral), marketed as Haldol, Haldol Solutab, Haloperidol and 2 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Haloperidol
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Conduct disorder
  • Mental or behavioural disorder
  • Psychosis
  • Schizoaffective disorder
  • Schizophrenia
  • Tics
  • Tourette syndrome

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Butyrophenone derivatives
FDA pharmacologic class
Typical Antipsychotic FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA51.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli44.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae31.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis68.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Haloperidol in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-8.5 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-6.9 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-9.6 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.5 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Haloperidol with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • A Study in the Treatment of Acute Mania

    NCT00767715 · start 2004-10

    Registered record
    Registry ID
    NCT00767715
    Conditions
    Bipolar Disorder
    Interventions
    olanzapine; haloperidol; zuclopentixol
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2004-10
    Completion
    2005-04
    Enrolment
    11

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBipolar Disorder
    Interventionolanzapine; haloperidol; zuclopentixol
    PhasePhase 4
    Registry statusTerminated

  • A Comparison of Study Drug With Placebo and Haloperidol in Patients With Schizophrenia

    NCT00044044 · start 2002-07

    Registered record
    Registry ID
    NCT00044044
    Conditions
    Schizophrenia
    Interventions
    Lurasidone 20 mg; Lurasidone 40mg; Lurasidone 80 mg; Haloperidol 10mg; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2002-07
    Completion
    2003-05
    Enrolment
    356

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia
    InterventionLurasidone 20 mg; Lurasidone 40mg; Lurasidone 80 mg; Haloperidol 10mg +1 more
    PhasePhase 2
    Registry statusCompleted

  • One Year Drug Treatment in First-Episode Schizophrenia

    NCT00159081 · start 2000-11

    Registered record
    Registry ID
    NCT00159081
    Conditions
    Schizophrenia
    Interventions
    Haloperidol, Risperidone (drug)
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2000-11
    Completion
    2005-06
    Enrolment
    159

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia
    InterventionHaloperidol, Risperidone (drug)
    PhasePhase 4
    Registry statusCompleted

  • Flupenthixol and Haloperidol for Treating Cocaine Abuse Schizophrenics - 9

    NCT00000274 · start 1997-03

    Registered record
    Registry ID
    NCT00000274
    Conditions
    Cocaine-Related Disorders; Substance-Related Disorders
    Interventions
    Flupenthixol
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    1997-03
    Completion
    1999-05
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCocaine-Related Disorders; Substance-Related Disorders
    InterventionFlupenthixol
    PhasePhase 2
    Registry statusCompleted

  • A Study of the Effectiveness and Safety of Risperidone Compared With Haloperidol and Placebo in Patients With Chronic Schizophrenia

    NCT00249132

    Registered record
    Registry ID
    NCT00249132
    Conditions
    Schizophrenia; Psychotic Disorders
    Interventions
    risperidone
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    Not recorded
    Completion
    1991-07
    Enrolment
    523

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia; Psychotic Disorders
    Interventionrisperidone
    PhasePhase 3
    Registry statusCompleted